Abstract
Parkinson’s disease is the second most common neurodegenerative disease in the world. Beta-arrestin-2 has been reported to be an important protein involved in D2 dopamine receptor desensitization, which is essential to Parkinson’s disease. Moreover, the potential value of pharmacological inactivation of G protein-coupled receptor kinase or arrestin in the treatment of patients with Parkinson’s disease has recently been shown. We studied the interaction between D2 dopamine receptor and beta-arrestin-2 and the pharmacological regulation of chemical compounds on such interaction using capillary zone electrophoresis. The results from screening more than 40 compounds revealed three compounds that remarkably inhibit the beta-arrestin-2/D2 dopamine receptor interaction among them. These compounds are promising therapies for Parkinson’s disease, and the method used in this study has great potential for application in large-scale drug screening and evaluation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Andersen, P.H., Gingrich, J.A., Bates, M.D., Dearry, A., Falardeau, P., Senogles, S.E., and Caron, M.G. (1990). Dopamine receptor subtypes: beyond the D1/D2 classification. Trends Pharmacol Sci 11, 231–236.
Calabresi, P., Mercuri, N.B., and Di Filippo, M. (2009). Synaptic plasticity, dopamine and Parkinson’s disease: one step ahead. Brain 132, 285–287.
Dagher, A., and Robbins, T.W. (2009). Personality, addiction, dopamine: insights from Parkinson’s disease. Neuron 61, 502–510.
DeWire, S.M., Ahn, S., Lefkowitz, R.J., and Shenoy, S.K. (2007). β-arrestins and cell signaling. Annu Rev Physiol 69, 483–510.
Ding, L., Zhang, X.X., Wei, P., Fan, K., and Lai, L. (2005). The interaction between severe acute respiratory syndrome coronavirus 3C-like proteinase and a dimeric inhibitor by capillary electrophoresis. Anal Biochem 343, 159–165.
Dodd, M.L., Klos, K.J., Bower, J.H., Geda, Y.E., Josephs, K.A., and Ahlskog, J.E. (2005). Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62, 1377–1381.
Dromey, J.R., and Pfleger, K.D. (2008). G protein coupled receptors as drug targets: the role of β-arrestins. Endocr Metab Immune Disord Drug Targets 8, 51–61.
Emilien, G., Maloteaux, J.M., Geurts, M., Hoogenberg, K., and Cragg, S. (1999). Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther 84, 133–156.
Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C.W., Tanner, C., and Marek, K., and the Parkinson Study Group. (2004). Levodopa and the progression of Parkinson’s disease. N Engl J Med 351, 2498–2508.
Gainetdinov, R.R., Premont, R.T., Bohn, L.M., Lefkowitz, R.J., and Caron, M.G. (2004). Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27, 107–144.
García-Campaña, A.M., Taverna, M., and Fabre, H. (2007). LIF detection of peptides and proteins in CE. Electrophoresis 28, 208–232.
Goldman-Rakic, P.S., Castner, S.A., Svensson, T.H., Siever, L.J., and Williams, G.V. (2004). Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174, 3–16.
Holzgrabe, U., Brinz, D., Kopec, S., Weber, C., and Bitar, Y. (2006). Why not using capillary electrophoresis in drug analysis? Electrophoresis 27, 2283–2292.
Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79, 368–376.
Kelly, E., Bailey, C.P., and Henderson, G. (2008). Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 153, S379–S388.
Kobilka, B.K., and Deupi, X. (2007). Conformational complexity of Gproteincoupled receptors. Trends Pharmacol Sci 28, 397–406.
Kostal, V., Katzenmeyer, J., and Arriaga, E.A. (2008). Capillary electrophoresis in bioanalysis. Anal Chem 80, 4533–4550.
Lefkowitz, R.J., and Shenoy, S.K. (2005). Transduction of receptor signals by β-arrestins. Science 308, 512–517.
Levoye, A., and Jockers, R. (2008). Alternative drug discovery approaches for orphan GPCRs. Drug Discov Today 13, 52–58.
Ma, L., and Pei, G. (2007). b-arrestin signaling and regulation of transcription. J Cell Sci 120, 213–218.
Macey, T.A., Gurevich, V.V., and Neve, K.A. (2004). Preferential Interaction between the dopamine D2 receptor and Arrestin2 in neostriatal neurons. Mol Pharmacol 66, 1635–1642.
Mehler-Wex, C., Riederer, P., and Gerlach, M. (2006). Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 10, 167–179.
Neve, K.A., Seamans, J.K., and Trantham-Davidson, H. (2004). Dopamine receptor signaling. J Recept Signal Transduct Res 24, 165–205.
Oakley, R.H., Laporte, S.A., Holt, J.A., Caron, M.G., and Barak, L.S. (2000). Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275, 17201–17210.
Obeso, J.A., Marin, C., Rodriguez-Oroz, C., Blesa, J., Benitez-Temiño, B., Mena-Segovia, J., Rodríguez, M., and Olanow, C.W. (2008). The basal ganglia in Parkinson’s disease: current concepts and unexplained observations. Ann Neurol 64, S30–S46.
Olanow, C.W., Obeso, J.A., and Stocchi, F. (2006). Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol 2, 382–392.
Premont, R.T., and Gainetdinov, R.R. (2007). Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69, 511–534.
Premont, R.T., Inglese, J., and Lefkowitz, R.J. (1995). Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 9, 175–182.
Reiter, E., and Lefkowitz, R.J. (2006). GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 17, 159–165.
Rosenbaum, D.M., Rasmussen, S.G., and Kobilka, B.K. (2009). The structure and function of G-protein-coupled receptors. Nature 459, 356–363.
Savitt, J.M., Dawson, V.L., and Dawson, T.M. (2006). Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116, 1744–1754.
Skinbjerg, M., Ariano, M.A., Thorsell, A., Heilig, M., Halldin, C., Innis, R.B., and Sibley, D.R. (2009). Arrestin3 mediates D(2) dopamine receptor internalization. Synapse 63, 621–624.
Whalen, E.J., Rajagopal, S., and Lefkowitz, R.J. (2011). Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med 17, 126–139.
Wilson, C.J., and Copeland, R.A. (1997). Spectroscopic characterization of arrestin interactions with competitive ligands: study of heparin and phytic acid binding. J Protein Chem 16, 755–763.
Xiao, K., Shenoy, S.K., Nobles, K., and Lefkowitz, R.J. (2004). Activation-dependent conformational changes in β-arrestin 2. J Biol Chem 279, 55744–55753.
Yang, P., Whelan, R.J., Mao, Y., Lee, A.W., Carter-Su, C., and Kennedy, R.T. (2007). Multiplexed detection of protein-peptide interaction and inhibition using capillary electrophoresis. Anal Chem 79, 1690–1695.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhou, Z., Liao, JM., Zhang, P. et al. Parkinson disease drug screening based on the interaction between D2 dopamine receptor and beta-arrestin 2 detected by capillary zone electrophoresis. Protein Cell 2, 899–905 (2011). https://doi.org/10.1007/s13238-011-1096-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13238-011-1096-0